Obesity could be treated by targeting mitochondrial defect, study finds
Scientists have discovered a new pharmacological approach to reduce the mitochondrial dysfunction that promotes diet-induced obesity in mice.
List view / Grid view
Scientists have discovered a new pharmacological approach to reduce the mitochondrial dysfunction that promotes diet-induced obesity in mice.
Scientists demonstrated how to reverse the incorrect localisation of three RNA-binding proteins in ALS, potentially leading to treatments.
Fenofibrate and its active form, fenofibric acid, have been shown to significantly reduce COVID-19 infection in human cells.
The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
Scientists have shown that manipulating the perineuronal nets (PNNs) in the brains of mice led to the reversal of age-related memory loss.
A new computer algorithm has identified highly conserved sequences in viral proteins that could make the best drug targets for COVID-19.
Researchers in Germany have identified 69 small molecules as binding partners for genomic RNA of SARS-CoV-2, possibly leading to new drugs.
UK researchers have created a metal-based molecule that inhibits the build-up of Alzheimer’s-associated peptide, amyloid-β, in lab tests.
Research by a team in Canada reveals a promising therapeutic target to counter HER2-positive breast cancer.
US researchers have identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that could be used against these targets.
Scientists have developed a compound that stops the degeneration of upper motor neurons, a contributor to amyotrophic lateral sclerosis (ALS).
Research has shown that MAPK4 activates two molecules in cellular signalling pathways involved in prostate cancer growth.
Research has shown that ACE2 and several integrins containing SLiMs are involved in SARS-CoV-2 infection, presenting new therapeutic targets.
A team has shown that STING activation is a new molecular target in the fight against graft-versus-host disease (GVHD).
Researchers have shown that a GLP-1/GIP dual-agonist targets the GIP receptor in the brain and CNS to reduce body weight and food intake.